
Luciana L Molinero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/414646/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	PARP Inhibitor Insensitivity to <i>BRCA1/2</i> Monoallelic Mutations in Microsatellite Instability-High Cancers. JCO Precision Oncology, 2022, , .	3.0	15
2	Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). Journal of Clinical Oncology, 2021, 39, 1842-1855.	1.6	183
3	Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study. Clinical Cancer Research, 2020, 26, 5631-5637.	7.0	31
4	Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecologic Oncology, 2019, 154, 314-322.	1.4	101
5	Cutting Edge: Engineering Active IKKβ in T Cells Drives Tumor Rejection. Journal of Immunology, 2016, 196, 2933-2938.	0.8	18
6	T cell-NF-l ^{$m B$} activation is required for tumor control in vivo. , 2015, 3, 1.		64
7	Basal NF-κB controls IL-7 responsiveness of quiescent naÃ⁻ve T cells. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 7397-7402.	7.1	30
8	T cell receptor/CARMA1/NF-κB signaling controls T-helper (Th) 17 differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 18529-18534.	7.1	50
9	High TCR Stimuli Prevent Induced Regulatory T Cell Differentiation in a NF-κB–Dependent Manner. Journal of Immunology, 2011, 186, 4609-4617.	0.8	78
10	CARMA1 Controls an Early Checkpoint in the Thymic Development of FoxP3+ Regulatory T Cells. Journal of Immunology, 2009, 182, 6736-6743.	0.8	99